What changed
$SNY — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.1B | EPS $1.10 vs $1.03 🟢
💡 Consensus models low single-digit revenue growth and stable margins; we estimate Dupixent indications (COPD, atopic dermatitis expansion) and cost restructuring will deliver mid-teens EPS growth, leading to positive estimate revisions and multiple rerating.
📉 Reward/risk: 2.33:1
🏢 Business Quality: 7/10
📊 Valuation: cheap
🔮 Catalyst: Phase 3 COPD trial results for Dupixent (BOREAS follow-up or NOTUS) expected within the next 2 months
💰 Entry: $43.8, stop $39.0, target $55.0
⚖️ Buy SNY for a near-term COPD catalyst and undervalued immunology growth; target $55, stop $39, risk/reward 2.3:1.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/SNY0616